Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases
Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics
Corcept Therapeutics Analyst Ratings
Unveiling 7 Analyst Insights On Avidity Biosciences
Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target
Avidity Biosciences Analyst Ratings
Crinetics Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Alkermes, Maintains $48 Price Target
Alkermes Analyst Ratings
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
How Is The Market Feeling About Krystal Biotech?
Immunovant Stock Falls 8% Amid Graves' Disease Program Update
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
Cantor Fitzgerald Reiterates Overweight on Immunovant
Immunovant Analyst Ratings
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Arcellx Analyst Ratings
Top 2 Health Care Stocks That May Collapse This Quarter
Immunovant Reports Phase 2a Results for Graves' Disease Drug, FDA Clears Pivotal Trial